Structure-activity relationship of verapamil analogs and reversal of multidrug resistance

G. Toffoli, F. Simone, G. Corona, M. Raschack, B. Cappelletto, M. Gigante, M. Boiocchi

Research output: Contribution to journalArticle

Abstract

We studied the relationship between the chemical structure and multidrug resistance (MDR) reversal activity of racemic verapamil (VER) and 14 VER analogs (VAs). The LoVo-R human colon carcinoma cell line was used as an experimental model. This cell line exhibited a typical MDR phenotype and overexpressed the MDR1 gene products. Key structural features were identified as being related to MDR reversal and cytotoxic activity. In particular, we demonstrated that the methoxy groups in the VER molecule structure [1.7-Bis-(3.4-dimethoxyphenyl) -3-methylaza-7-cyan-8-methyl-nonane] prevented cytotoxicity when the VAs were used alone, whereas the 7-cyan-8-methyl groups were important for MDR reversal activity and interaction with P-glycoprotein (P-gp). Among the VAs tested, the most active compounds were gallopamil, R-isomer of VER (R-VER), and nor-VER, which potentiated doxorubicin (DOX) cytotoxicity by 52.3 ± 7.2 (n = 3 ± SD), 38.9 ± 6.4 (n = 4 ± SD), and 35.4 ± 4.3 (n = 3 ± SD) times, respectively. The reversal activity of these compounds was similar to that of VER, which enhanced DOX cytotoxicity by 41.3 ± 5.0 (n = 3 ± SD) times. The potentiation of DOX cytotoxicity was associated with an increase in DOX uptake in LoVo-R cells and with an increased [3H]azidopine P-gp photolabeling inhibition. Some compounds that had a high reversal potency (i.e. R-VER and nor-VER) showed a lower calcium antagonist activity than VER, and seem useful candidates for the treatment of MDR in cancer patients.

Original languageEnglish
Pages (from-to)1245-1255
Number of pages11
JournalBiochemical Pharmacology
Volume50
Issue number8
DOIs
Publication statusPublished - Oct 12 1995

Fingerprint

Multiple Drug Resistance
Structure-Activity Relationship
Verapamil
Cytotoxicity
Doxorubicin
P-Glycoprotein
Isomers
Cells
Gallopamil
Cell Line
Colon
Theoretical Models
Genes
Calcium
Carcinoma
Phenotype
Molecules

Keywords

  • multidrug resistance
  • P-glycoprotein
  • verapamil

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. / Toffoli, G.; Simone, F.; Corona, G.; Raschack, M.; Cappelletto, B.; Gigante, M.; Boiocchi, M.

In: Biochemical Pharmacology, Vol. 50, No. 8, 12.10.1995, p. 1245-1255.

Research output: Contribution to journalArticle

Toffoli, G. ; Simone, F. ; Corona, G. ; Raschack, M. ; Cappelletto, B. ; Gigante, M. ; Boiocchi, M. / Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. In: Biochemical Pharmacology. 1995 ; Vol. 50, No. 8. pp. 1245-1255.
@article{5e92116b39574976bbee777f1aa8dd36,
title = "Structure-activity relationship of verapamil analogs and reversal of multidrug resistance",
abstract = "We studied the relationship between the chemical structure and multidrug resistance (MDR) reversal activity of racemic verapamil (VER) and 14 VER analogs (VAs). The LoVo-R human colon carcinoma cell line was used as an experimental model. This cell line exhibited a typical MDR phenotype and overexpressed the MDR1 gene products. Key structural features were identified as being related to MDR reversal and cytotoxic activity. In particular, we demonstrated that the methoxy groups in the VER molecule structure [1.7-Bis-(3.4-dimethoxyphenyl) -3-methylaza-7-cyan-8-methyl-nonane] prevented cytotoxicity when the VAs were used alone, whereas the 7-cyan-8-methyl groups were important for MDR reversal activity and interaction with P-glycoprotein (P-gp). Among the VAs tested, the most active compounds were gallopamil, R-isomer of VER (R-VER), and nor-VER, which potentiated doxorubicin (DOX) cytotoxicity by 52.3 ± 7.2 (n = 3 ± SD), 38.9 ± 6.4 (n = 4 ± SD), and 35.4 ± 4.3 (n = 3 ± SD) times, respectively. The reversal activity of these compounds was similar to that of VER, which enhanced DOX cytotoxicity by 41.3 ± 5.0 (n = 3 ± SD) times. The potentiation of DOX cytotoxicity was associated with an increase in DOX uptake in LoVo-R cells and with an increased [3H]azidopine P-gp photolabeling inhibition. Some compounds that had a high reversal potency (i.e. R-VER and nor-VER) showed a lower calcium antagonist activity than VER, and seem useful candidates for the treatment of MDR in cancer patients.",
keywords = "multidrug resistance, P-glycoprotein, verapamil",
author = "G. Toffoli and F. Simone and G. Corona and M. Raschack and B. Cappelletto and M. Gigante and M. Boiocchi",
year = "1995",
month = "10",
day = "12",
doi = "10.1016/0006-2952(95)02003-U",
language = "English",
volume = "50",
pages = "1245--1255",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Structure-activity relationship of verapamil analogs and reversal of multidrug resistance

AU - Toffoli, G.

AU - Simone, F.

AU - Corona, G.

AU - Raschack, M.

AU - Cappelletto, B.

AU - Gigante, M.

AU - Boiocchi, M.

PY - 1995/10/12

Y1 - 1995/10/12

N2 - We studied the relationship between the chemical structure and multidrug resistance (MDR) reversal activity of racemic verapamil (VER) and 14 VER analogs (VAs). The LoVo-R human colon carcinoma cell line was used as an experimental model. This cell line exhibited a typical MDR phenotype and overexpressed the MDR1 gene products. Key structural features were identified as being related to MDR reversal and cytotoxic activity. In particular, we demonstrated that the methoxy groups in the VER molecule structure [1.7-Bis-(3.4-dimethoxyphenyl) -3-methylaza-7-cyan-8-methyl-nonane] prevented cytotoxicity when the VAs were used alone, whereas the 7-cyan-8-methyl groups were important for MDR reversal activity and interaction with P-glycoprotein (P-gp). Among the VAs tested, the most active compounds were gallopamil, R-isomer of VER (R-VER), and nor-VER, which potentiated doxorubicin (DOX) cytotoxicity by 52.3 ± 7.2 (n = 3 ± SD), 38.9 ± 6.4 (n = 4 ± SD), and 35.4 ± 4.3 (n = 3 ± SD) times, respectively. The reversal activity of these compounds was similar to that of VER, which enhanced DOX cytotoxicity by 41.3 ± 5.0 (n = 3 ± SD) times. The potentiation of DOX cytotoxicity was associated with an increase in DOX uptake in LoVo-R cells and with an increased [3H]azidopine P-gp photolabeling inhibition. Some compounds that had a high reversal potency (i.e. R-VER and nor-VER) showed a lower calcium antagonist activity than VER, and seem useful candidates for the treatment of MDR in cancer patients.

AB - We studied the relationship between the chemical structure and multidrug resistance (MDR) reversal activity of racemic verapamil (VER) and 14 VER analogs (VAs). The LoVo-R human colon carcinoma cell line was used as an experimental model. This cell line exhibited a typical MDR phenotype and overexpressed the MDR1 gene products. Key structural features were identified as being related to MDR reversal and cytotoxic activity. In particular, we demonstrated that the methoxy groups in the VER molecule structure [1.7-Bis-(3.4-dimethoxyphenyl) -3-methylaza-7-cyan-8-methyl-nonane] prevented cytotoxicity when the VAs were used alone, whereas the 7-cyan-8-methyl groups were important for MDR reversal activity and interaction with P-glycoprotein (P-gp). Among the VAs tested, the most active compounds were gallopamil, R-isomer of VER (R-VER), and nor-VER, which potentiated doxorubicin (DOX) cytotoxicity by 52.3 ± 7.2 (n = 3 ± SD), 38.9 ± 6.4 (n = 4 ± SD), and 35.4 ± 4.3 (n = 3 ± SD) times, respectively. The reversal activity of these compounds was similar to that of VER, which enhanced DOX cytotoxicity by 41.3 ± 5.0 (n = 3 ± SD) times. The potentiation of DOX cytotoxicity was associated with an increase in DOX uptake in LoVo-R cells and with an increased [3H]azidopine P-gp photolabeling inhibition. Some compounds that had a high reversal potency (i.e. R-VER and nor-VER) showed a lower calcium antagonist activity than VER, and seem useful candidates for the treatment of MDR in cancer patients.

KW - multidrug resistance

KW - P-glycoprotein

KW - verapamil

UR - http://www.scopus.com/inward/record.url?scp=0028793277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028793277&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(95)02003-U

DO - 10.1016/0006-2952(95)02003-U

M3 - Article

C2 - 7488241

AN - SCOPUS:0028793277

VL - 50

SP - 1245

EP - 1255

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 8

ER -